Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
REDWOOD CITY, Calif., Feb. 21, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2016 financial results will be released after market close on Monday, March 13, 2017. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing fourth quarter and full year 2016 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.
Conference Call Information
When: Monday, March 13, 2017 at 4:30 p.m. ET
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 66529524
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O’Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
